Skip to content
ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. technical analysis

ACADHealthcare Updated daily

Technical analysis of ACADIA Pharmaceuticals Inc. (stock) with the Montbon Method — Elliott Waves, moving averages and a 0–100 score.

What is ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company focused on the development and commercialization of medicines for neurological and rare diseases in North America. Its marketed products include NUPLAZID (pimavanserin) for Parkinson's disease psychosis and DAYBUE (trofinetide) for the treatment of Rett syndrome. The company also has several candidates in clinical development for indications such as Alzheimer's disease psychosis, major depressive disorder, and essential tremor.

Description generated automatically from public sources; it may be inaccurate or out of date.

ACADIA Pharmaceuticals Inc.: latest session data

Closing values for September 4, 2026, computed on the last 12 months of prices.

Close28.02 $
Change+0.57%
RSI (14)47.1
MACD0.397
ADX30.4
Volatility (ATR)3.22%
Volume vs 20-avg115%
12-month high30.96 $
12-month low19.89 $

Moving averages

21 sessions

29.20 $

−4.05%

50 sessions

27.29 $

+2.69%

200 sessions

24.47 $

+14.52%

Session levels

s2

26.73

Support

s1

27.30

Support

pivot

28.18

Pivot

r1

28.75

Resistance

r2

29.63

Resistance

How to read it

In the September 4, 2026 session ACADIA Pharmaceuticals Inc. closed higher at 28.02 $, +0.57% versus the previous session.

The price sits mixed against its moving averages: −4.05% against the 21-session average, +2.69% against the 50 and +14.52% against the 200.

The 14-period RSI reads 47.1, in neutral territory.

MACD stands at 0.397 against a signal line at 0.742: the histogram is negative (−0.344).

ADX reads 30.4, indicating a marked directionality.

Levels computed on the latest session place supports at 27.30 and 26.73 $ and resistances at 28.75 and 29.63 $, around a pivot of 28.18.

The average daily range (ATR) is 0.904 $, or 3.22% of price.

Turnover was 1.7M shares, 115% of the 20-session average.

Over the last twelve months the price ranged between 19.89 and 30.96 $, and today stands −9.50% from the period high.

Measures computed on closing prices. They describe the past; they are not forecasts.

Open the full analysis of ACADIA Pharmaceuticals Inc.

Score, Elliott Waves, moving averages and technical indicators — free, no card

If you're not registered we'll ask you to sign in (free), then open the ACAD analysis.

How Montbon’s technical analysis works

Montbon analyses markets with Elliott Waves, multi-timeframe moving averages and a 0–100 score summarising the technical setup. It is an informational screening tool.

Elliott Waves

Wave counting to frame the price structure.

MTF moving averages

Moving averages across timeframes to read the trend.

0–100 score

A technical summary of the setup, updated daily.

Read the full Montbon Score methodology →

FAQ about ACADIA Pharmaceuticals Inc.

What technical indicators are commonly used to analyze a stock like ACAD?

For a healthcare sector stock like ACAD, analysts often use momentum indicators such as RSI and MACD, moving averages to identify the underlying trend, and Bollinger Bands to measure volatility. These tools help contextualize price movements independently of company fundamentals.

On which timeframes is it useful to observe the technical analysis of ACAD?

Technical analysis of ACAD can be conducted across different timeframes: daily and weekly charts are often used to identify medium-to-long-term trends, while 15-minute or 60-minute charts may be used for a closer observation of shorter-term price fluctuations.

What are Elliott Waves and how do they apply to a stock like ACAD?

Elliott Wave Theory is a technical analysis method that proposes prices move in repetitive sequences of impulsive and corrective waves. Applied to ACAD, it involves searching for recurring structures in the price chart, though its interpretation requires experience and may differ among analysts.

Other tickers to analyse

Disclaimer. For informational purposes only; not financial advice or a recommendation. Montbon Analytics is not an authorised financial intermediary.

Are you an issuer and want a correction or removal? Write to info@montbon.com.